MSK-ACCESS® powered with SOPHiA DDM™

MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of the highly validated liquid biopsy assay developed and routinely used by Memorial Sloan Kettering Cancer Center (MSK), involving the deep sequencing (~20,000x) of 147 key cancer-associated genes, from extracted cell-free DNA (cfDNA) to comprehensive report in ~5 days.

Assess 147 key cancer-associated genes curated by MSK experts, leveraging a matched tumor-normal workflow to distinguish somatic from germline and CHIP variants.

Sample-to-report bundle: capture-based target enrichment and library preparation kit combined with the analytical capabilities of the SOPHiA DDM™ Platform.

Specifications

Elevate your precision oncology program

Push the boundaries of your in-house liquid biopsy research capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK) 1,2.

Discover an innovative solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform for paradigm-shifting liquid biopsy insights.

Expert knowledge-driven design – Focus on what matters with a comprehensive 147 gene panel curated by MSK experts.

Robust analytical performance – Trust your results with demonstrated 99.4% positive percent agreement (≥0.5% VAF) to MSK-ACCESS® used at MSK³.

End-to-end application – Save time with a streamlined workflow, taking you from cfDNA sample to report in ∼5 days.

Insights over time – Maximize insights with variant calling across sequential tests, facilitating longitudinal monitoring.

Detection of true somatic variants – Increase confidence in your variant calling by filtering out clonal hematopoietic and germline variants with a matched tumor-normal approach

Enhanced interpretation support – Leverage user-friendly interpretation features, including access to MSK’s Precision Oncology Knowledge Base, OncoKB™.

Save time with a streamlined end-to-end workflow

Equip your laboratory with a true sample-to-report workflow that combines in-house hybrid capture and cloud-based analytics, allowing you to to retain ownership of your samples and data.

Easy library preparation and capture

• 147 gene panel, curated by MSK experts and selected from MSK’s cancer genomic profiling assay, MSK-IMPACT®
• Hybridization-based capture with deep sequencing (~20,000x)
• Tailored probes for high on-target rate and coverage uniformity
• Minimal input amount of only 20 ng cfDNA
• Ready-to-sequence libraries in just 1.5 days
• Optimized multiplexing of paired tumor-normal samples for a cost-effective process
• Incorporation of matched normal sample requires only 20% of sequencing space
• Compatible with Illumina®, Complete Genomics/MGI and Element sequencers

Advanced analysis with the SOPHiA DDM™ Platform – Somatic mutations accumulate in cells with a hematopoietic lineage (e.g. stem cells in the bone marrow) as we age or in response to environmental influences. These mutations are known as CHIP. CHIP mutations can be detected in the plasma and wrongly attributed to solid tumor origins 4,5.

• Algorithm-powered detection of SNVs, Indels, CNV, fusions, and MSI
• Proprietary molecular identifier technology, CUMIN®, for sensitive variant detection down to 0.5% VAF
• Tertiary analysis based on the latest scientific evidence on relevant variants with OncoPortal™ Knowledge Base​
• Access via hyperlink to MSK’s Precision Oncology Knowledge Base, OncoKB™, for enhanced interpretation support
• Knowledge-sharing within SOPHiA GENETICS Community, a unique network of connected healthcare institutions

Increase confidence in your variant calling with a matched tumor-normal approach

Clonal hematopoiesis of indeterminate potential (CHIP) is a common cause of biological false positives in cfDNA analysis. MSK-ACCESS® powered with SOPHiA DDM™ leverages a matched tumor-normal approach that enables CHIP filtering and eliminates the risk of:

By sequencing tumor-derived cfDNA and normal white blood cell DNA in parallel, you can effectively reduce noise in your data analysis and focus on tumor-specific somatic variants.

• Biological false positives at low allele frequencies (e.g. in BRCA1).
• Removing true positives, if using only database-driven approaches to annotate CHIP.

Trust your data – In an end-to-end comparison of 48 cfDNA + matched white blood cell DNA samples, MSK-ACCESS® powered with SOPHiA DDM™ achieved 99.4% positive percent agreement (≥0.5% VAF) with the centralized version used at MSK.

VAF, variant allele frequency. a) Based on end-to-end concordance analysis between MSK-ACCESS® powered with SOPHiA DDM™ and centralized version of MSK-ACCESS® at MSK, using 48 cfDNA + matched WBC DNA samples; b) Correlation of variant allele fraction to reference method.

Searching for robust insights? Let SOPHiA DDM™ search for you – The trusted analytics and advanced features of the SOPHiA DDM™ Platform enable the accurate detection and characterization of complex genomic variants, while adhering to the most up-to-date international guidelines.

OncoPortal™ Knowledge Base further supports decision-making and reporting by matching tumor molecular profiles with clinical associations and available clinical trials. I n addition, the application offers access to MSK ’s Precision Oncology Knowledge Base, OncoKB™, via a link in SOPHiA DDM™ for comprehensive genomic insights.

Addressing global inequalities in comprehensive cancer care – AstraZeneca and MSK have joined forces with SOPHiA GENETICS to revolutionize cancer research. Together, we are creating a decentralized global network for liquid biopsy testing, including underserved regions where access remains scarce.

Generating an unparalleled and comprehensive dataset sourced from diverse populations holds the potential for invaluable insights that could shape the future of global healthcare.

Documents

• Fact Sheet: MSK-ACCESS® powered with SOPHiA DDM™ (RUO)
• Flyer: MSK-ACCESS® powered with SOPHiA DDM™ (RUO)

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.